This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
by Kinjel Shah
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
GSKNegative Net Change NVOPositive Net Change LLYNegative Net Change ABBVNegative Net Change
pharmaceuticals
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
by Kinjel Shah
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Top Stock Reports for Johnson & Johnson, Oracle & Netflix
by Mark Vickery
Johnson & Johnson, Oracle and Netflix lead Zacks' top stock reports as analysts spotlight growth drivers, cloud gains and new monetization efforts.
AEENegative Net Change JNJNegative Net Change NFLXNegative Net Change ORCLPositive Net Change ESPNegative Net Change AXONPositive Net Change CRDOPositive Net Change
aerospace computers consumer-discretionary pharmaceuticals
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
by Zacks Equity Research
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
RHHBYPositive Net Change MRKNegative Net Change EXELNegative Net Change NTRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
by Zacks Equity Research
Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
LQDANegative Net Change IMCRNegative Net Change ERNANegative Net Change INDVNegative Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion
by Kinjel Shah
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
AZNPositive Net Change JNJNegative Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals
Silver Economy Investing: Why the Healthcare Giants Are in Focus
by Urmimala Biswas
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
ABTNegative Net Change LLYNegative Net Change MDTNegative Net Change ISRGPositive Net Change RMDNegative Net Change TNDMPositive Net Change
biotechs cell-therapy healthcare medical medical-devices pharmaceuticals
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
by Ekta Bagri
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
by Zacks Equity Research
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
REGNNegative Net Change BMYPositive Net Change MRKNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
by Aparajita Dutta
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
AZNPositive Net Change NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change HRTSNegative Net Change THNRPositive Net Change OZEMPositive Net Change
etfs medical pharmaceuticals